A Retrospective Study of Amyloid‐Related Imaging Abnormalities in Patients Receiving Lecanemab for the Treatment of Alzheimer's Disease
Real-world data of ARIA incidence, severity, and APOE genotype associations closely match the data obtained in the CLARITY-AD trial, providing further evidence to support the overall safety of lecanemab in routine clinical practice as guided by appropriate use recommendations. References: 1 - van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948.
Authors
- Cindy L. Marshall
- Oliver Zhou
- Claudia Padilla
- Alexander Andrew Wallace
Institutions
- Baylor University Medical Center (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099951
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00